PRESS RELEASE Priority access for children during Myozyme supply shortage
Posted on: January 16, 2009
The European Medicines Agency’s (EMEA) Committee for Medicinal Products (CHMP) has recommended that infants, children and adolescents be given priority access to Myozyme (alglucosidase alfa), from Genzyme, during the expected supply shortage of the medicine over the next few months. This is intended to ensure that these patients continue to receive Myozyme while the company solves its supply problems.